“Is curing patients a sustainable business model?” Goldman Sachs analysts ask

Enlarge / The Goldman Sachs bank logo is seen reflected on the screen of a mobile phone in this photo illustration on November 15, 2017. (credit: Jaap Arriens/NurPhoto via Getty Images)

One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.

The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer is “no,” according to follow-up information provided.

Analyst Salveen Richter and colleagues laid it out:

Read 4 remaining paragraphs

Source: FS – All – Science – News
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask